Study of the natural history of gangliosidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people with gangliosidosis to better understand how the condition changes over time. You may be asked to complete thinking/behavior tests and, if you have late-onset disease, get a head MRI (a painless scan) to help researchers track changes in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of gangliosidosis (documented in your records)
- You can complete memory/thinking and behavior-related assessments
- If you have late-onset gangliosidosis, you can tolerate a head MRI scan
- You are willing to participate in follow-up assessments over time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial follows people with genetic neurodegenerative (brain-wasting) disorders over time to better understand how the condition changes. The goal is to learn patterns that could help future treatments or care plans.
This trial tests a new oral medicine, nizubaglustat (AZ-3102), for children and adults (4+) with late-infantile or juvenile Niemann-Pick type C, GM1, or GM2 gangliosidosis. It aims to see if the drug is safe and helps slow disease progression.
This study looks at how your symptoms, brain imaging (MRI), and genetic factors relate to neurodegenerative conditions. It may help researchers better understand what causes these illnesses and how to classify them.
This study follows people with certain inherited metabolic conditions (like GM1 or GM2 gangliosidosis, sialidosis, or galactosialidosis) to learn more about how these diseases progress over time. Participating may help researchers understand the conditions better, which could improve future care.
This study looks at the potential of gene therapy to treat GM2 gangliosidosis, a rare inherited disease that affects the brain and nerves. By studying blood samples, researchers hope to learn more about how the disease works and whether gene therapy might be a future treatment option.
This early-stage study tests an IV gene therapy that delivers a working copy of an enzyme gene to help the body make beta-galactosidase in GM1 gangliosidosis. It may help slow or improve disease symptoms and looks closely at safety and how well the treatment works.
Hear when a new Tay-Sachs Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.